Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Horizon Therapeutics (HZNP) PT Lowered to $162 at Goldman Sachs
May 4, 2022 3:50 PM EDTGoldman Sachs analyst Madhu Kumar lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $162.00 (from $169.00) while maintaining a Buy rating following earnings.
The analyst commented, "Recognizing near-term headwinds for Tepezza related to carryover from omicron delays from 1Q22 into 2Q22,... More
Horizon Therapeutics (HZNP) Tops Q1 EPS by 20c; Maintains Outlook
May 4, 2022 7:10 AM EDTHorizon Therapeutics (NASDAQ: HZNP) reported Q1 EPS of $1.34, $0.20 better than the analyst estimate of $1.14. Revenue for the quarter came in at $885.2 million versus the consensus estimate of $874.41 million.
GUIDANCE:
Horizon Therapeutics maintains its FY2022 revenue outlook of $3.9-4 billion, versus the... More
